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Objectives: Preoperative duplex scanning of arm and forearm veins has increased the creation of autogenous arteriovenous
(AV) fistulas. However, the cumulative functional patency and durability of transposed AV fistulas (TAVF) compared
with nontransposed AV fistulas (AVF) and prosthetic bridging grafts (AVG) remains ill-defined.
Methods: From January 1998 to December 2002, 245 dialysis access procedures were performed at University Hospital
and the Veteran Affairs Medical Center in New Jersey. Follow-up data were available for 125 procedures (TAVF, n 42;
AVF, n  30; AVG, n  53) performed in 97 patients. All access procedures were planned on the basis of preoperative
duplex scans of arm and forearm veins. Functional patency was defined as ability to cannulate and hemodialyze patients
successfully. Primary and secondary cumulative functional patency of TAVFs, AVFs, and AVGs was determined with life
table analysis, and differences were analyzed with the log-rank test. Differences in revision rates, including thrombolysis,
thrombectomies, and operative revisions, were determined with the Fisher exact t test.
Results: Mean follow-up was 18 months (range, 4-24 months). For TAVFs, AVFs, and AVGs, primary functional patency
rate at 1 year was 76.2%, 53.3%, and 47.2%, respectively, and at 2 years was 67.7%, 34.4%, and 25.5%, respectively.
Similarly, secondary functional patency rate at 1 year was 83.2%, 66.7%, and 58.5%, respectively, and at 2 years was 74.6%,
56.2%, and 40.2%, respectively. Primary and secondary functional patency rates for TAVFs were superior to those for
AVGs at 1 and 2 years (P < .001). AVFs had superior secondary functional patency rate at 2 years, compared with AVGs
(P < .05), and TAVFs had superior primary and secondary patency rates at 2 years, compared with AVFs (P < .05). AVGs
required significantly more revisions than did TAVFs (28.5% vs 54.7%; P < .001) or AVFs (36.7% vs 54.7%; P < .05).
Conclusions: Preoperative duplex scanning of upper arm and forearm veins facilitated successful creation of all types of
autogenous fistulas at our institution. TAVF cumulative functional patency rates were superior compared with AVGs and
AVFs. Furthermore, TAVFs and AVFs were more durable and required fewer revisions than did AVGs. When
preoperative duplex criteria indicate that TAVFs can be performed, they should be the initial access of choice, because of
their superior long-term patency and durability. (J Vasc Surg 2003;38:1206-12.)
Vascular access procedures and their subsequent com-
plications are a major cause of morbidity, hospitalization,
and cost for patients receiving chronic hemodialysis.1-3
According to the National Kidney Foundation Dialysis
Outcomes Quality Initiative (DOQI) Clinical Practice
Guidelines for Vascular Access, the ideal hemodialysis ac-
cess graft would prove durable, provide superior hemodi-
alysis, demonstrate a low incidence of infection, and require
few interventions to maintain patency. This document sug-
gests that autogenous arteriovenous (AV) fistulas approxi-
mate the ideal access graft. As a result, they recommend
that “primary” AV fistulas should be constructed in at least
50% of all new patients with kidney failure who elect to
receive hemodialysis as the initial form of renal replacement
therapy. Ultimately, 40% of prevalent patients should have
a native AV fistula.4 Despite these national recommenda-
tions, only about 30% of patients beginning hemodialysis in
the United States currently have an autogenous AV fistula
as the primary dialysis access.5
Multiple studies have demonstrated that autogenous
AV fistulas demonstrate superior overall patency and lower
revision rates compared with prosthetic grafts.6-8 Autoge-
nous fistulas are less prone to recurrent stenosis, thrombo-
sis, or infection.9 However, some investigators have re-
ported that if failure to mature is included in assessing
autogenous fistula patency, there are no differences in
access rate and overall function when compared with pros-
thetic grafts.10,11 Demographic factors that decrease fistula
maturation include advanced age, gender, African-Ameri-
can race, diabetes mellitus, and obesity. All of these factors
are associated with small vessels with diminished blood
flow.12 However, the DOQI guidelines do not recommend
a specific type of autogenous fistula. While the introduction
of the Brescia-Cimino fistula in 1966 has led to its common
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and successful use, several reports suggest that upper ex-
tremity fistulas and vein translocation procedures may dem-
onstrate superior performance characteristics.10-14 We
therefore reviewed our clinical experience with transposed
AV fistulas (TAVF), nontransposed AV fistulas (AVF), and
prosthetic bridge grafts (AVG) to determine the relative
effect of access type on functional patency, on the basis of
preoperative duplex scans of arm and forearm veins.
METHODS
From January 1998 to December 2002, 245 hemodi-
alysis access procedures were performed in 157 consecutive
patients in a single university program. Follow-up data for
125 procedures (TAVF, n  42; AVF, n  30; AVG, n 
53) in 97 patients were available for analysis. The proce-
dures were performed by five vascular surgeons, all with
extensive experience and multiple publications on hemodi-
alysis access. Information regarding patient demographic
data, preoperative diagnostic workup, procedure, and out-
come were collected through chart review, follow-up tele-
phone calls, office visits, and review of hemodialysis
records. As a result of loss of the outpatient hemodialysis
unit at University Hospital, record retrieval and follow-up
were difficult. As a result, 60 patients with 120 procedures
were lost to follow-up. Functional patency was defined as
ability to deliver adequate flow rate greater than 350 mL/s
to maintain treatment time less than 4 hours without access
recirculation.15 Time to primary functional patency was
determined as amount of time between access placement
and either permanent failure or first revision requiring a
procedure to maintain or restore patency. Secondary func-
tional patency was determined as amount of time between
access placement and permanent access failure.
Preoperative upper extremity vein mapping with
duplex ultrasound (US) scanning. All upper extremity
arm and forearm veins in patients requiring long-term
hemodialysis were evaluated with duplex US scanning, as
described.16 Duplex scanning was performed by registered
vascular technologists and interpreted by vascular surgeons
in an International Commission for Accreditation of Vas-
cular Laboratories–accredited laboratory. In brief, the su-
perficial veins of the nondominant arm are evaluated at
ultrasonography, starting at the wrist with a tourniquet
placed at mid-forearm. The veins are assessed for compress-
ibility and diameter with a 5-MHz or 7-MHz scanning
probe after release of the tourniquet. The antecubital space
is evaluated for continuity of the forearm veins and of the
deep system through the axillary and subclavian veins. No
specific duplex scanning criteria or protocol exists for place-
ment of TAVF versus AVF, except for vein size for all
autogenous fistulas. Access type is based on surgeon pref-
erence; three of the five surgeons perform TAVFs primarily,
and the other two surgeons perform TAVFs but on occa-
sion perform AVFs. Forearm or wrist veins larger than 2
mm in diameter or arm veins larger than 2.5 mm in diam-
eter were considered appropriate for either AVF or TAVF
creation. In patients with veins smaller than 2 mm in
diameter in the forearm or 2.5 mm in diameter in the arm,
AVGs were placed if the antecubital veins were larger than
3 mm in diameter. The skin was marked preoperatively in
all patients. The inflow artery was considered appropriate if
it was larger than 2.0 mm in diameter and without signifi-
cant calcification.
Technique for creation of forearm TAVF. Access
procedures were performed with the patient under general
anesthesia, axillary block, or local anesthesia with sedation,
as considered appropriate by the operating team. The pro-
cedures were performed on an outpatient basis as same-day
surgery. The vein is dissected from the wrist into the
forearm 15 to 20 cm, with ligation of all branches. A
superficial tunnel is then created in the volar aspect of the
forearm, directed to the arterial inflow source. The dis-
sected vein is marked to prevent rotation and then brought
through the tunnel. An end-to-side anastomosis with
polypropylene sutures is performed, and the incisions are
closed with running absorbable sutures.13
Technique for creation of arm TAVF. The cephalic
vein is dissected and transposed in a superficial tunnel with
an end-to-side anastomosis to the brachial artery. Alterna-
tively, the basilic vein is exposed through a medial longitu-
dinal incision to where it joins the brachial vein. The
brachial artery is dissected through the same incision. The
basilic vein is tunneled superficially, and an end-to-side
anastomosis to the brachial artery is performed.
Technique for nontransposed AVF. Radiocephalic
and brachiocephalic AVFs is performed with an end-to-side
anastomosis, usually through a single incision. The venous
branches are not ligated beyond the limits of the incision.
Technique for prosthetic bridge grafts. When an
AVG was indicated, all patients received 6 mm polytetraflu-
orethylene grafts, which were tunneled superficially. The
two locations used for this access were brachial artery to
axillary vein in the arm or brachial artery to median cubital,
cephalic, or basilic vein in the cubital fossa, in a looped
configuration.
Statistical analysis. Primary and secondary functional
patency rates were calculated with life table analysis in
accordance with Society for Vascular Surgery/American
Association for Vascular Surgery reporting standards for
lower extremity ischemia.17 Differences between patency
rates for TAVF, AVF, and AVG were determined with the
log rank test. Differences in procedure revision rates were
determined with the Fisher exact test. Patient demographic
data were compared between groups with a pair-wise t test.
RESULTS
Patient population. Over the 4-year review, data
were available for 97 patients in whom 125 hemodialysis
accesses were placed. Patients were stratified into three
groups: TAVF (n 42), AVF (n 30), and AVG (n 53).
Patient demographic data for all groups are outlined in
Table I. No differences in age, gender, or medical comor-
bidities were observed, except for the incidence of diabetes
mellitus. Specifically, the prevalence of diabetes mellitus
was greater in the TAVF and AVG groups compared with
the AVF group (P  .005). No significant difference in
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incidence of diabetes was observed between the TAVF and
AVG groups. Mean preoperative vein size was not different
between the AVF group (3.41 mm; range, 2.0-4.8 mm)
and the TAVF group (3.51 mm; range, 2.0-5.4 mm; dif-
ference not significant). The male predominance in the
study is reflective of the number of access procedures
performed at our Veterans Administration hospital.
Hemodialysis access. Overall, TAVFs and AVFs dem-
onstrated better functional patency compared with AVGs.
Both primary and secondary functional patency rates for
TAVFs were significantly improved at both 1 and 2 years,
compared with that for AVGs (P  .005). However, when
comparing patency rates for TAVFs and AVFs, a difference
was observed at 2 years. Specifically, at 1 year TAVFs and
AVFs had similar patency rates. However, at 2 years both
the primary and secondary functional patency rates were
superior in the TAVF group compared with the AVF group
(P  .05; Tables II and III, Figs 1 and 2). No significant
difference in patency was noted between forearm TAVFs,
AVFs, and AVGs and arm TAVFs, AVFs, and AVGs (Table
IV). Thirty-five of 53 patients (66%) in the AVG group, 22
of 42 patients (52%) in the TAVF group, and 5 of 30
Table I. Demographic data
TAVF AVF AVG
n % n % n %
Total procedures 42 30 53
Male 34 81 24 80 42 79
Age (y)
Mean 58.3 57.2 61.9
Range 37-85 31-81 44-81
Diabetes 30 71 9 30* 34 64
Hypertension 32 76 22 73 45 85
TAVF, Transposed arteriovenous fistula; AVF, nontransposed arteriovenous fistula; AVG, prosthetic bridging graft.
*P  .005, AVF compared with AVG and TAVF.















patency (%) SE (%)
A. Prosthetic bridging grafts
0-1 53 11 0 0 0 0.21 0.79 100 0.00
1-3 42 6 0 0 0 0.14 0.86 79.25 5.57
3-6 36 8 0 0 0 0.22 0.78 67.92 6.41
6-9 28 3 0 0 0 0.11 0.89 52.83 6.86
9-12 25 3 0 0 0 0.12 0.88 47.17 6.86
12-15 22 3 2 0 0 0.14 0.86 41.51 6.77
15-18 17 2 1 0 1 0.13 0.88 35.58 6.93
18-21 13 2 2 0 2 0.18 0.82 31.13 7.17
21-24 7 3 1 0 1 0.50 0.50 25.47 8.31
B. Transposed arteriovenous fistulas
0-1 42 0 0 0 0 0.00 0.00 100.00 0.00
1-3 42 5 0 0 0 0.12 0.88 100.00 0.00
3-6 37 5 0 0 0 0.14 0.86 88.10 5.00
6-9 32 0 2 0 0 0.00 1.00 76.19 6.57
9-12 30 1 0 0 0 0.03 0.97 76.19 6.79
12-15 29 1 2 0 0 0.04 0.96 73.65 7.02
15-18 26 0 2 0 0 0.00 1.00 71.02 7.5
18-21 23 1 3 0 0 0.05 0.95 71.02 7.97
21-24 19 2 2 0 0 0.11 0.89 67.72 8.83
C. Nontransposed arteriovenous fistulas
0-1 30 9 0 0 0 0.30 0.70 100.00 0.00
1-3 21 5 0 0 0 0.24 0.76 70.00 8.37
3-6 16 0 0 0 0 0.00 1.00 53.33 9.11
6-9 16 0 0 0 0 0.00 1.00 53.33 9.11
9-12 16 1 1 0 0 0.06 0.94 53.33 9.11
12-15 14 2 1 0 0 0.15 0.85 49.89 9.44
15-18 11 0 0 0 0 0.00 1.00 42.50 9.72
18-21 11 2 1 0 0 0.19 0.81 42.50 9.72
21-24 8 2 2 0 0 0.29 0.71 34.41 9.85
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patients (16.7%) in the AVF group had a history of access
failure. Secondary patency rates in patients with history of
access failure were 57.1% for AVGs, 60% for AVFs, and
74.6% for TAVFs at 2 years, which was not significantly
different from patency rates in patients without a history of
access failure (difference not significant).
Fistula maturation. TAVFs had a significantly lower
nonmaturation rate (2 of 42, 4.7% compared with AVFs (8
of 30, 26.7%; P  .02). Six of the eight AVFs were
subsequently revised; however, only two successfully
matured.
Durability. AVGs required significantly more revisions
than either TAVFs or AVFs. Thirty-two revisions were
required for AVGs (55%; P  .05), 12 for TAVFs (24%),
and 12 for AVFs (33%). No statistical difference was noted
in revision rates between TAVFs and AVFs (Table V).














patency (%) SE (%)
A. Prosthetic bridging grafts
0-1 53 11 0 0 0 0.21 0.79 100.00 0.00
1-3 42 4 0 0 0 0.10 0.90 79.25 5.57
3-6 38 4 0 0 0 0.11 0.89 71.70 6.19
6-9 34 3 0 0 0 0.09 0.91 64.15 6.59
9-12 31 3 0 0 0 0.10 0.90 58.49 6.77
12-15 28 3 2 0 0 0.11 0.89 52.83 6.86
15-18 23 2 1 0 1 0.09 0.91 46.96 7.13
18-21 19 1 2 0 2 0.06 0.94 42.69 7.41
21-24 14 1 1 0 1 0.08 0.92 40.18 8.31
B. Transposed arteriovenous fistulas
0-1 42 0 0 0 0 0.00 1.00 100.00 0.00
1-3 42 4 0 0 0 0.10 0.90 100.00 0.00
3-6 38 3 0 0 1 0.08 0.92 90.48 4.53
6-9 34 0 2 0 0 0.00 1.00 83.24 5.84
9-12 32 1 0 0 0 0.03 0.97 83.24 6.02
12-15 31 1 2 0 0 0.03 0.97 80.64 6.37
15-18 28 0 3 0 0 0.00 1.00 77.95 6.92
18-21 25 1 3 0 0 0.04 0.96 77.95 7.32
21-24 21 1 2 0 0 0.05 0.95 74.63 8.2
C. Nontransposed arteriovenous fistulas
0-1 30 9 0 0 0 0.30 0.70 100.00 0.00
1-3 21 1 0 0 0 0.05 0.95 70.00 8.37
3-6 20 0 0 0 0 0.00 1.00 66.67 8.61
6-9 20 0 0 0 0 0.00 1.00 66.67 8.61
9-12 20 1 1 0 0 0.05 0.95 66.67 8.61
12-15 18 2 1 0 0 0.11 0.89 63.25 9.04
15-18 15 0 0 0 0 0.00 1.00 56.02 9.59
18-21 15 0 1 0 0 0.00 1.00 56.02 9.59
21-24 13 1 2 0 0 0.08 0.92 56.02 9.93
Fig 1. Primary functional patency survival curves. TAVF, Trans-
posed arteriovenous fistula; AVF, nontransposed arteriovenous
fistula; AVG, prosthetic bridging graft.
Fig 2. Secondary functional patency survival curves. TAVF,
Transposed arteriovenous fistula; AVF, nontransposed arterio-
venous fistula; AVG, prosthetic bridging graft.
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Complications. Complications observed after place-
ment of hemodialysis access included hematoma, lympho-
cele, symptomatic steal, and infection. The only significant
difference in morbidity was the increased observation of
infections associated with AVGs (P  .01). No 30-day
mortality occurred with any access procedure in our series
(Table VI).
DISCUSSION
In 1997 the DOQI group published a series of recom-
mendations regarding management in patients requiring
long-term hemodialysis.4 These guidelines strongly recom-
mend creation of autogenous fistulas as the dialysis access of
choice in patients requiring hemodialysis. After initial pub-
lication of the DOQI guidelines, several published reports
indicated that autogenous fistulas are more durable and
demonstrate better long-term patency compared with
prosthetic bridging grafts.6-8 Specifically, autogenous fistu-
las require fewer revisions to maintain patency and have a
low infection rate compared with prosthetic bridging
grafts.18-19 Using a noninvasive vascular laboratory proto-
col for preoperative vein mapping, our institution has suc-
cessfully increased the number of autogenous fistulas avail-
able for hemodialysis.16 However, the type of autogenous
fistula and whether utility of forearm vein affects functional
fistula use remains ill-defined.
Historically, traditional Brescia-Cimino–type fistulas
have not demonstrated widespread popularity, because of a
reported failure to mature rate of 9% to 56% leading to a
nonfunctional autogenous fistula.10,11,20 Data from the
current series confirms this observation. Nontransposed
AVFs demonstrated nonmaturation rates of 26.7% (8 of
30), which decreased to 20% (6 of 30) after operative
revision. Nonrevised AVFs had a significantly lower matu-
ration rate compared with TAVFs (26.7% vs 4.7%; P .02).
This finding was observed although fewer patients with
diabetes were in the AVF group than in the TAVF group.
Proponents indicate that TAVFs demonstrate better func-
tional maturation rates in the arms of patients with diabetes
compared with traditional radiocephalic fistulas.14 The su-
perior maturation is probably related to ligation of side
branches, which increases shear stress and placement of the
vein in a more superficial location.21 This observation has
led some authors to propose a two-stage fistula procedure;
in the first stage a traditional autogenous fistula is created,
and in the second procedure the side branches are elevated
and ligated. Furthermore, this procedure has been recom-
mended as a salvage technique for matured AVFs that are
not accessible because of their deep location in the arm or
forearm.22,23 A recent report by Hossney et al24 compared
the one-stage venous transposition operation with the two-
stage elevation procedure in the arm, and reported no
difference in patency rate. However, the complication rate
was significantly higher in the two-stage elevation group
compared with the one-stage transposition group (71.4% vs
28.6%; P  .001).24 Complications consisted primarily of
edema and puncture site hematoma, which were major
predisposing factors associated with fistula failure in the
two-stage elevation group. Furthermore, Gibson et al8
reported that in 2247 newly placed hemodialysis access
procedures, TAVFs outperformed AVFs and AVGs in pa-
tients with a history of hemodialysis access failure. Our data
did not demonstrate a difference in patency rate in patients
with a history of access failure, regardless of access type
(difference not significant). Our higher patency rate may be
the result of selection bias. On the basis of preoperative
duplex scanning criteria, veins deemed usable for autoge-
nous fistulas must be greater than 2.0 mm in diameter and
lack evidence of phlebitis or mechanical defects to proceed
with fistula creation. Furthermore, only veins larger than 3
mm in the antecubital fossa and arm are used for AVG
venous anastomosis. Therefore a selection bias for success-
ful maturation and patency of fistulas and bridging grafts is
present in the current series. Furthermore, 29 of 30 AVFs
Table V. Revisions
TAVF AVF AVG




Percent revised 24 (10/42) 37 (11/30) 55 (29/53)
TAVF, Transposed arteriovenous fistula; AVF, nontransposed arteriovenous
fistula; AVG, prosthetic bridging graft.
*P  .05, AVF compared with TAVF.
Table VI. Complications requiring operative intervention
Infection Hematoma Steal Lymphocele
n % n % n % n %
AVG 7 13* 0 1 1.9 1 1.9
AVF 0 0 0 0
TAVF 0 2 4.7 0 0
TAVF, Transposed arteriovenous fistula; AVF, nontransposed arteriovenous
fistula; AVG, prosthetic bridging graft.
*P  .01, TAVF compared with AVF.
Table IV. Patency rates and location of dialysis access
Access location Total
Patency rate (%)
One year Two years
Forearm TAVF 22 72.73 63.03
Arm TAVF 20 84.55 75.15
Forearm AVG 38 51.52 36.36
Arm AVG 15 60 52.94
Forearm AVF 29 51.18 36.36
Arm AVF 1 100 0
TAVF, Transposed arteriovenous fistula; AVF, nontransposed arteriovenous
fistula; AVG, prosthetic bridging graft.
*P  NS, forearm location compared with arm location.
JOURNAL OF VASCULAR SURGERY
December 20031210 Choi et al
were radiocephalic fistulas at the wrist, and this study does
not address whether arm AVFs would have demonstrated
better functional patency. Since the original description by
Dagher et al25 of TAVFs using basilic vein, numerous
reports have emphasized the superiority of basilic vein
TAVFs compared with AVFs.26,27 However, the high inci-
dence of forearm vein phlebitis secondary to previous intra-
venous cannulation or venipuncture injury caused by fre-
quent blood drawing, have raised concerns about the
effectiveness of forearm veins for autogenous fistula use.
Furthermore, few investigators have compared the utility of
forearm veins versus arm veins for creation of autogenous
AV fistulas. Of the 42 TAVFs in the current series, 22 were
forearm transpositions. There were no differences in func-
tional patency compared with arm TAVFs (difference not
significant). Furthermore, our data indicate that TAVFs
have better functional patency compared with AVFs and
AVGs. AVFs and TAVFs were also more durable, requiring
fewer interventions to maintain patency. These data em-
phasize the importance of our preoperative noninvasive
laboratory vein assessment, resulting in better patient selec-
tion and increased fistula patency. What remains unclear is
whether preoperative vein assessment with duplex US scan-
ning can identify patients in whom AVFs will be durable
and functional over the long term, eliminating the need for
a long vein harvest scar and a second incision for AV
anastomosis. To recommend widespread use of TAVFs, a
randomized prospective trial comparing TAVFs and AVFs
is required.
In conclusion, TAVFs demonstrated better long-term
patency and required fewer revisions at 24 months com-
pared with AVFs and AVGs. The improved performance of
TAVFs is secondary to proper selection of veins at preop-
erative duplex US scanning, and ligation of side branches
leading to a high rate of maturation. Furthermore, these
data indicate that properly selected forearm veins are
equally as effective as arm veins when used for TAVFs.
Therefore forearm veins should be used whenever possible,
to save access sites more proximally for future use. Future
investigations should focus on whether duplex scanning
criteria can identify patients in whom functional AVFs will
result, negating the need for long harvest incisions.
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